State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?

The article compares two healthcare-focused ETFs: State Street SPDR S&P Pharmaceuticals (XPH) and First Trust NYSE Arca Biotechnology Index Fund (FBT). XPH offers lower costs (0.35% expense ratio vs 0.55%), broader diversification with 59 holdings, and better 1-year performance (38% vs 35.90%), plus dividend income. FBT provides more concentrated biotech exposure with 30 holdings. The analysis concludes XPH is the more appealing long-term choice due to its lower fees and superior performance.

06/04/2026, 1:13 PM • The Motley Fool

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT

Pomerantz Law Firm has filed class action lawsuits against Corcept Therapeutics, Eos Energy Enterprises, and Nektar Therapeutics. The primary case involves Corcept, which faced a 50.4% stock price decline after the FDA issued a Complete Response Letter for its relacorilant drug, citing insufficient evidence of effectiveness. Investors with losses are urged to contact the firm by the April 21, 2026 deadline to potentially serve as lead plaintiff.

04/21/2026, 3:56 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Corcept Therapeutics Incorporated (NASDAQ: CORT) alleging that company executives made materially false and misleading statements about the clinical trial strength and regulatory prospects of their drug relacorilant. The complaint claims defendants overstated the drug's approval chances while concealing known FDA concerns about insufficient clinical evidence supporting the New Drug Application.

04/21/2026, 12:00 PM • GlobeNewswire

CORCEPT DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Corcept Therapeutics Incorporated Investors to Contact the Firm Regarding Their Rights Before April 21st

A class action lawsuit has been filed against Corcept Therapeutics for allegedly misleading investors about its relacorilant drug candidate for Cushing's syndrome. The company claimed the clinical trials provided 'powerful support' for FDA approval, but the FDA issued a Complete Response Letter citing insufficient evidence of effectiveness. Corcept's stock plummeted 50.4% following the December 31, 2025 disclosure. Investors who purchased shares between October 31, 2024, and December 30, 2025, have until April 21, 2026, to apply as lead plaintiffs.

04/20/2026, 12:59 PM • GlobeNewswire

CORT 3-DAY DEADLINE ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Approaching April 21st Lead Plaintiff Deadline in Securities Fraud Class Action Over Relacorilant Failure

Hagens Berman is alerting Corcept Therapeutics (CORT) investors of an April 21, 2026 lead plaintiff deadline in a securities fraud class action. The lawsuit alleges Corcept concealed FDA warnings about insufficient clinical data for its lead drug relacorilant while publicly expressing confidence in approval. The FDA issued a Complete Response Letter on December 31, 2025, causing CORT stock to crash 50% from $70.20 to $34.80, erasing $2.5 billion in market value.

04/18/2026, 8:21 PM • GlobeNewswire

CORT DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action – CORT

Rosen Law Firm is alerting investors in Corcept Therapeutics (CORT) who suffered losses exceeding $100K to join a securities class action lawsuit before the April 21, 2026 deadline. The lawsuit alleges that Corcept misrepresented the strength of clinical trial data supporting its relacorilant drug application to the FDA, while concealing known material risks of non-approval. Similar class actions have been filed against Alight, Inc. and Soleno Therapeutics, Inc.

04/18/2026, 9:37 AM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Corcept Therapeutics Incorporated alleging that company executives made materially false and misleading statements about the clinical trial strength and regulatory prospects of their drug relacorilant. The lawsuit claims defendants overstated the drug's approval likelihood while the FDA had raised significant concerns about the clinical evidence supporting the New Drug Application. Investors who purchased Corcept securities between October 31, 2024 and December 30, 2025 are encouraged to join the case.

04/17/2026, 12:00 PM • GlobeNewswire

CORT Shareholder Alert: April 21, 2026 Lead Plaintiff Deadline in Corcept Therapeutics Incorporated Securities Class Action Lawsuit — The Gross Law Firm

The Gross Law Firm announces a securities class action lawsuit against Corcept Therapeutics (CORT) for allegedly making false and misleading statements regarding FDA interactions and expectations for relacorilant NDA approval. The lawsuit covers the period from October 31, 2024 to December 30, 2025, with a lead plaintiff deadline of April 21, 2026. Shareholders who purchased CORT shares during this period are encouraged to register for potential recovery.

04/17/2026, 9:00 AM • GlobeNewswire

CORT 1-WEEK DEADLINE ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Approaching April 21st Lead Plaintiff Deadline in Securities Fraud Class Action Over Relacorilant Failure

Hagens Berman alerts Corcept Therapeutics (CORT) investors of an April 21, 2026 lead plaintiff deadline in a securities fraud class action. The lawsuit alleges Corcept concealed FDA warnings about insufficient clinical data for its lead drug relacorilant while publicly expressing confidence in approval. The FDA issued a Complete Response Letter on December 31, 2025, causing CORT stock to plummet 50% from $70.20 to $34.80, erasing $2.5 billion in market value.

04/14/2026, 12:57 PM • GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated and Encourages Investors to Contact the Firm

A class action lawsuit has been filed against Corcept Therapeutics for allegedly misleading investors about its relacorilant drug candidate for Cushing's syndrome. The company claimed the clinical trials provided 'powerful support' for FDA approval, but the FDA issued a Complete Response Letter citing insufficient evidence of effectiveness. Corcept's stock plummeted 50.4% following the December 31, 2025 disclosure. Investors who purchased shares between October 31, 2024, and December 30, 2025, are eligible to participate in the lawsuit.

04/13/2026, 5:58 PM • GlobeNewswire

Corcept Therapeutics Incorporated Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – CORT

Levi & Korsinsky filed a class action securities lawsuit against Corcept Therapeutics for alleged fraud between October 31, 2024 and December 30, 2025. The complaint alleges that defendants made false statements about FDA interactions regarding relacorilant's NDA approval prospects, when the FDA had actually expressed concerns about the drug's effectiveness assessment program and the GRACE study design. Investors who suffered losses during this period can request lead plaintiff status by April 21, 2026.

04/13/2026, 2:59 PM • GlobeNewswire

INVESTOR DEADLINE: Corcept Therapeutics (CORT) Investors with Substantial Losses Have Opportunity to Lead the Corcept Class Action Lawsuit– Hagens Berman

Hagens Berman announced a securities class action lawsuit against Corcept Therapeutics (CORT) for allegedly concealing FDA warnings about its lead drug relacorilant while publicly expressing confidence in approval. The FDA issued a Complete Response Letter on December 31, 2025, citing insufficient evidence of effectiveness, causing CORT's stock to crash 50% from $70.20 to $34.80 in a single day. Investors with losses between October 31, 2024, and December 30, 2025, have until April 21, 2026, to become lead plaintiffs.

04/10/2026, 1:56 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Corcept Therapeutics Incorporated for alleged securities fraud. The complaint alleges that defendants made materially false and misleading statements about the strength of clinical trials supporting relacorilant and overstated confidence in its regulatory approval prospects, while failing to disclose that the FDA had raised concerns about the adequacy of clinical evidence supporting the NDA.

04/10/2026, 12:00 PM • GlobeNewswire

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Corcept Therapeutics Incorporated (CORT), Lakeland Industries, Inc. (LAKE), and Navan, Inc. (NAVN) Announced by Holzer & Holzer, LLC

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Corcept Therapeutics, Lakeland Industries, and Navan, Inc. The lawsuits allege materially false statements and/or failure to disclose material facts regarding clinical trials, business operations, and sales/marketing expenses respectively. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by the announced deadlines in April 2026.

04/09/2026, 8:00 AM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Corcept Therapeutics Incorporated for alleged securities fraud. The complaint alleges that defendants made materially false and misleading statements about the strength of clinical trials supporting relacorilant and overstated confidence in its regulatory approval prospects, while failing to disclose that the FDA had raised concerns about the adequacy of clinical evidence. Investors who purchased Corcept securities between October 31, 2024 and December 30, 2025 are encouraged to join the case, with a lead plaintiff deadline of April 21, 2026.

04/07/2026, 12:00 PM • GlobeNewswire